Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that both oral tranexamic acid and microneedling improve melasma treatment outcomes when added to standard therapy, with microneedling showing a more sustained remission.

This study developed dissolving microneedles using specific polymers for transdermal delivery of rizatriptan benzoate, demonstrating improved drug skin penetration and significant alleviation of migraine symptoms in vivo compared to passive diffusion, suggesting potential advantages over conventional treatment methods for acute migraine.

This study found that topical treatment with Maneb led to delayed epithelial cell degeneration in hair follicles of rats due to apoptosis.

In this study, researchers developed and tested a novel peptide, AMHR2BP, which mimics the function of Anti-Müllerian hormone to protect ovarian follicles in mice, showing promise for preserving ovarian health during chemotherapy without causing toxicity.

This study found that combining the PAXMAN scalp cooling system with HairRepro MEDI α lotion led to a 50% success rate in reducing chemotherapy-induced alopecia and achieved complete hair regrowth by 3 months in Japanese breast cancer patients, suggesting enhanced efficacy over scalp cooling alone.

In this summary of needle mesotherapy's role in treating alopecia, the researchers highlight its use in delivering beneficial substances directly to the skin or hair follicles, showing hair loss reduction after one treatment and hair regrowth after several sessions, although contraindications exist for certain populations.

This case report documented the management of a 46-year-old female with Marine-Lenhart syndrome, combining antithyroids with minimally invasive sclerotherapy to achieve euthyroidism and reduce thyroid nodule size by 58%.

This case report highlights a rare instance of minoxidil-induced pleuro-pericardial effusion with tamponade in a patient with end-stage renal disease on hemodialysis, which improved following pericardiocentesis and discontinuation of the drug.

In this retrospective study from North France, apremilast was used in patients with psoriasis and recent cancer, showing a good safety profile and improved quality of life, though with 65.2% experiencing non-serious adverse events. The need for further research on oncological safety was highlighted.

This article discusses arsenic trioxide as a treatment for refractory or relapsed acute promyelocytic leukemia, noting its effectiveness and manageable side effects.

This study found that the combination of MT-DADMe-ImmA and MTA selectively induced apoptosis in head and neck squamous cell carcinoma cell lines FaDu and Cal27, but not in normal fibroblasts or MTAP-deficient breast cancer cells.

This study found that a biocomposite microneedle system, which includes selenium nanozyme and hypoxic extracellular vesicles, enhanced hair density and follicle diameter in androgenetic alopecia mice by fighting inflammation, promoting blood vessel growth, reducing reactive oxygen species, and counteracting androgen effects.

This study found that mycophenolate mofetil was associated with higher response rates and lower rates of serious side effects, including a lower mortality rate, compared to cyclophosphamide in lupus nephritis treatment.

This study reported that a novel vasodilator drug called TOP-M119, when delivered using a specially designed dissolving microneedle system, showed enhanced targeting of hair follicles and effectiveness in treating alopecia, demonstrated through in vitro, ex vivo, and in vivo studies involving mouse skin.

This case study reports a 15-year-old Burmese girl with telogen effluvium after receiving incorrect medication due to a pharmacy auto-complete error.

This correspondence highlights a case of intradermal minoxidil injection in a patient but does not report new research findings.

In this mouse study, applying a vasoconstrictor before chemotherapy did not create a leukemia sanctuary or significantly impact survival outcomes, suggesting it may not interfere with leukemia treatment.

This study found that therapeutic isolated limb perfusion with melphalan for in-transit melanoma metastases resulted in a high response rate but was associated with some systemic toxicity, including nausea, vomiting, and transient bone marrow depression.

This study suggests that combining monoammonium glycyrrhizinate/glycine/DL-methionine tablets with 5% carpronium chloride may reduce alopecia areata area more effectively than carpronium chloride alone, particularly in patients with allergic factors.

The authors concluded that mesotherapy is a new, effective, and safer dermatologic treatment option for conditions like alopecia, skin rejuvenation, and hyperpigmentation due to its efficiency and reduced treatment time.

Certain peptides can prevent hair loss in young rats caused by a cancer drug.

In this study, a patient with Cronkhite-Canada syndrome complicated by severe sepsis and disseminated intravascular coagulation was successfully treated using combined therapies, including recombinant human soluble thrombomodulin, despite the absence of a standard treatment regimen for CCS.

This study reports that hair mesotherapy can achieve positive clinical outcomes for scalp diseases, particularly when used by expert dermatologists. It is primarily used alongside standard treatments, and as a standalone option only when other treatments are contraindicated or ineffective.

This study found that ALRN-6924, a clinical-stage dual inhibitor, can selectively protect human scalp hair follicles from paclitaxel-induced toxicity and damage by inducing transient cell cycle arrest in healthy cells without affecting cancer cells, potentially reducing chemotherapy-induced alopecia.

This article reviews the dermatologic conditions associated with hemodialysis, such as pruritus, xerosis cutis, and skin infections, and does not present new findings.

This study found that mesotherapy combined with minoxidil for androgenetic alopecia shows promise with high patient satisfaction and manageable risks, though some uncommon side effects may occur.

This study found that topical application of recombinant human MG53 protein mitigated nitrogen mustard-induced skin injuries in mice by preserving epidermal integrity and hair follicle structure.

In this case study, a 43-year-old male with anti-GBM disease experienced a relapse triggered by hair dye, leading to diffuse alveolar hemorrhage; managing this with plasmapheresis, intravenous immunoglobulins, and rituximab suggests rituximab may be beneficial for relapsing cases.